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Abstract Although imatinib is an effective treatment for chronic myelogenous
leukemia (CML), and nearly all patients treated with imatinib attain some form of re
mission, imatinib does not completely eliminate leukemia. Moreover, if the imatinib
treatment is stopped, most patients eventually relapse (Cortes et al. in Clin. Can
cer Res. 11:3425–3432, 2005). In Kim et al. (PLoS Comput. Biol. 4(6):e1000095,
2008), the authors presented a mathematical model for the dynamics of CML un
der imatinib treatment that incorporates the anti-leukemia immune response. We use
the mathematical model in Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008) to
study and numerically simulate strategic treatment interruptions as a potential ther
apeutic strategy for CML patients. We present the results of numerous simulated
treatment programs in which imatinib treatment is temporarily stopped to stimulate
and leverage the anti-leukemia immune response to combat CML. The simulations
presented in this paper imply that treatment programs that involve strategic treatment
interruptions may prevent leukemia from relapsing and may prevent remission for
signiﬁcantly longer than continuous imatinib treatment. Moreover, in many cases,
strategic treatment interruptions may completely eliminate leukemic cells from the
body. Thus, strategic treatment interruptions may be a feasible clinical approach to

enhancing the effects of imatinib treatment for CML. We study the effects of both
the timing and the duration of the treatment interruption on the results of the treat
ment. We also present a sensitivity analysis of the results to the parameters in the
mathematical model.
Keywords Chronic myelogenous leukemia · Imatinib · Mathematical model ·
Strategic treatment interruptions

1 Introduction
Chronic myelogenous leukemia (CML) results from the uncontrolled growth of white
blood cells due to increased and unregulated growth of predominantly myeloid cells
in the bone marrow and the accumulation of these cells in the blood (Sawyers 2000).
The standard treatment for CML is the tyrosine kinase inhibitor imatinib mesylate
(marketed as Gleevec or Glivec) (Angstreich et al. 2004). Although imatinib is an
effective treatment for CML and most patients attain some form of remission, ima
tinib does not completely eliminate all leukemia cells, and if the imatinib treatment
is stopped, most patients eventually relapse (Cortes et al. 2005; Michor et al. 2005)
(though we do note that in some recent clinical ﬁndings, e.g., (Rousselot et al. 2007;
Mahon et al. 2009), several patients have demonstrated relapse-free survival after
imatinib discontinuation). There are three standard types of remission: hematologic,
cytogenetic, and molecular. Each layer corresponds to a 2-log, or 100-fold, difference
from the previous layer. According to (Lowenberg 2003), each patient typically has
approximately 1012 leukemia cells prior to imatinib treatment. Hence, hematologic
remission corresponds to 1010 cells, cytogenetic remission corresponds to 108 cells,
and molecular remission corresponds to 106 cells. Assuming that the average person
has approximately 6 liters of blood, these remission levels correspond to the concen
tration levels given in Table 1. With imatinib treatment, nearly all patients achieve
hematologic remission (Lee 2000), and approximately 75% of patients achieve cyto
genetic remission (Cortes et al. 2005).
Several recent mathematical models have been developed to study the dynam
ics of CML under imatinib treatment, including (Komarova and Wodarz 2005;
Michor et al. 2005; Kim et al. 2008), and (Roeder et al. 2006). In all of these studies,
the authors conclude that imatinib does not completely eliminate the leukemia cell
population, and propose that imatinib therapy should be combined with an additional
form of treatment. In (Michor et al. 2005), the authors develop a four-compartment
differential equations model based on the known biology of the hematopoietic sys
tem to model the dynamics of CML with imatinib treatment. In (Kim et al. 2008), the
authors incorporate the anti-leukemia immune response in CML patients on imatinib
Table 1 Leukemia cell concentrations (in k/µL) corresponding to hematologic, cytogenetic, and molecu
lar remission levels
Remission level

Hematologic

Cytogenetic

Molecular

Concentration (k/µL)

1.67

1.67 × 10−2

1.67 × 10−4

therapy to the model proposed in (Michor et al. 2005) by adding interactions with
anti-leukemia T-cells. The authors of (Kim et al. 2008) formulate their mathematical
model as a system of delay-differential equations (DDEs), and demonstrate that the
immune response may play a critical role in determining the length of time that CML
patients on imatinib treatment remain in remission.
In this paper, we present a strategic treatment interruption treatment strategy for
CML based on the delay differential equation model proposed in (Kim et al. 2008).
We use the model in (Kim et al. 2008) to numerically determine an optimal time
period during which imatinib treatment should be temporarily stopped in order to
leverage the anti-leukemia immune response. Although the leukemia load initially
suppresses the T-cell immune response, a small number of T-cells remain and can
eventually be leveraged to potentially eradicate leukemia. We demonstrate that such
a strategic treatment interruption signiﬁcantly improves the efﬁcacy of imatinib treat
ment for CML patients. In particular, the results of our simulations suggest that, in
many cases, leukemia can be completely eliminated with a strategic treatment inter
ruption timed during the patient’s own anti-leukemia immune response. In (Kim et
al. 2008), the authors consider total leukemia elimination to be complete if the total
cancer population in the body is below 1 cell, i.e.,
Total cancer concentration < 10−10 k/µL,
assuming that the average patient has about 6 L of blood. Since the mathematical
model presented in (Kim et al. 2008) is a continuous deterministic system, in reality,
the model never allows the total cancer population to actually reach 0. Since a total
cancer concentration of 10−10 k/µL corresponds to less than one cancer cell in the
blood, this is a reasonable indicator for total cancer elimination.
This paper is organized in the following way. In Sect. 2, we provide an overview
of the delay-differential equation model for the dynamics of CML, imatinib, and the
anti-leukemia immune response presented in (Kim et al. 2008). In Sect. 3, we propose
several strategic treatment interruption treatment programs for CML patients based
on the anti-leukemia immune response described in (Kim et al. 2008), and we present
and analyze the results of these simulated treatment plans. In particular, we study
the effects of changing the timing and duration of the treatment interruption on the
time required for the patient to achieve cytogenetic remission and (in many cases)
the time required for total cancer elimination. In Sect. 4, we study the sensitivity of
the results to the universal and patient-speciﬁc parameters used in the mathematical
model. We discuss conclusions, drawbacks of the mathematical model used for our
numerical analysis, and areas for further research in Sect. 5. In Appendix A, we derive
an explicit, closed-form solution for the mathematical model for CML presented in
(Michor et al. 2005).

2 A Mathematical Model for CML with Imatinib Treatment
Michor et al. (2005), used data from 169 patients to develop and analyze a mathemat
ical model for CML. In this model, leukemia cells are assumed to develop through
four stages of differentiation. The different cell populations at time t are denoted as

follows: y0 (t), leukemia stem cells; y1 (t), progenitor cells; y2 (t), differentiated cells;
and y3 (t), terminally differentiated cells. Leukemia cells progress through the vari
ous stages in the following way. Stem cells regenerate themselves at rate ry . Stem
cells expand and progress to become progenitor cells at rate ay and die at rate r0 .
Progenitor cells become differentiated cells at rate by and die at rate d1 . Differen
tiated cells expand and progress to become terminal cells at rate cy and die at rate
d2 . Terminal cells die at rate d3 . With imatinib treatment, the rate at which leukemia
cells pass from one stage to the next is greatly reduced, thus causing a rapid drop
in the leukemia population. In particular, according to this model, imatinib treatment
reduces the parameters ay and by by 100-fold and 750-fold, respectively. For the ini
tial conditions, it is assumed that all four leukemia compartments are in steady state
relative to one another.
In addition, Michor et al. included a second set of leukemia cells to incorporate
the possibility of imatinib-resistant mutations. It was assumed that the only cells that
can acquire imatinib-resistant mutations are stem cells, and they mutate at a rate u
per division. In this paper, we will assume that there are no imatinib-resistant muta
tions (i.e., u = 0), so we do not include the second set of differential equations here.
However, we describe them in Appendix A. The system of ODEs that describes the
model for the leukemia cell populations is given below. Although Michor et al. did
not derive an explicit solution for this system of differential equations in their origi
nal work, the system can be solved exactly using diagonalization and we present the
solution in Appendix A:
dy0
dt
dy1
dt
dy2
dt
dy3
dt

�
�
= ry (1 − u) − d0 y0 ,
= ay y 0 − d1 y 1 ,
= by y 1 − d2 y 2 ,
= cy y 2 − d3 y 3 .

In (Kim et al. 2008), the authors modiﬁed this model to incorporate an antileukemia immune T-cell response into the ODE model. The motivation for their
model is based on experimental data taken from (Chen et al. 2008), in which the
authors conducted TNF-α and IFN-γ ELISPOT analyses at multiple time points to
measure the evolution of the anti-leukemia T-cell responses of CML patients under
going imatinib treatment. To incorporate the dynamics of the imatinib-induced T-cell
immune response in the system of equations governing the CML dynamics, the au
thors of (Kim et al. 2008) added interactions with T-cells and a delay-differential
equation to model the T-cell population. In the modiﬁed system, each equation con
tains an added term which accounts for the death of leukemia cells as a result of an
interaction with T-cells. In addition, a delay-differential equation is included for the
population T of anti-leukemia T-cells. The leukemia cell death rates di , 0 ≤ i ≤ 3,

in (Michor et al. 2005) correspond to the natural death rates of the leukemia popula
tions under imatinib treatment. In the DDE model of (Kim et al. 2008), the authors
distinguish between the natural death rate of leukemia and the death rate due to the
cytotoxic T-cell response. Thus, the death rates di in the DDE model are a fraction, λ,
of the combined death rates estimated in (Michor et al. 2005). The parameter λ rep
resents the fraction of the leukemia cell deaths that results from nonimmune (versus
immune) causes. It is assumed that λ is greater than 0.5, so that the anti-leukemia im
mune response contributes to less than half of the decline in leukemia under imatinib
treatment (Kim et al. 2008). In (Kim et al. 2008), the authors set λ = 0.75; we include
a discussion of the sensitivity of our results on the choice of λ. Following (Kim et al.
2008), we assume that u = 0 and that there are no imatinib-resistant leukemia cells. In
Sect. 5, we discuss the possibility of acquired imatinib resistance. The mathematical
model which includes the immune response is given by the following:
dy0
dt
dy1
dt
dy2
dt
dy3
dt

= (ry − d0 )y0 − qC p(C, T )y0 ,
= ay y0 − d1 y1 − qC p(C, T )y1 ,
(1)
= by y1 − d2 y2 − qC p(C, T )y2 ,
= cy y2 − d3 y3 − qC p(C, T )y3 ,

dT
= sT − dT T − p(C, T )C + 2n p(Cnτ , Tnτ )qT Cnτ ,
dt

(2)

where
p(C, T ) = p0 e−cn C kT ,

C=

3
�

yi ,

i=0

Cnτ = C(t − nτ ),

Tnτ = T (t − nτ ).

The variables in this model are the same as those in the model of Michor et al.
(2005), with the exception of the new variables C and T . The variable C represents
the total concentration of all leukemia cells. The variable T represents the concen
tration of anti-leukemia T cells. The ﬁnal terms qC p0 e−cn C kT yi follow the law of
mass action. The kT yi is the rate of interaction between anti-leukemia T-cells and
the leukemia cell subpopulation yi , where k is the mixing coefﬁcient. The coefﬁ
cient p0 is the probability that a T-cell engages the cancer cell upon interaction, and
qC is the probability that the cancer cell dies from the T-cell response. Moreover,
leukemia cells suppress the anti-leukemia T-cell immune response, and although the
precise mechanism is unknown, this model assumes that the level of down-regulation
depends on the current cancer population. The probability that a T-cell engages a can
cer cell is modeled as an exponential decay as a function of the cancer concentration.
Thus, the probability of a productive T-cell interaction with a cancer cell is p0 e−cn C ,
where cn is the rate of exponential decay due to negative pressure. We note that the

authors of Kim et al. (2008) model T-cell dynamics in particular because T-cells are
the main mediators of the anti-leukemia response, as has been demonstrated by the
major role that cytotoxic T-cells play in curing leukemia after an allogenic stem cell
transplant. By extension, they are hypothesizing that autologous T-cells will also be
the key players in the anti-leukemia immune response.
In the delay-differential equation (2) for modeling the anti-leukemia T-cell re
sponse, the parameter sT denotes the constant supply rate of T-cells into the system
from stem cells. The parameter dT represents the natural death rate of T-cells, and
p(C, T )C is the rate at which T-cells engage leukemia cells and commit to n rounds
of division. The ﬁnal term represents the population increase due to n divisions of
stimulated T-cells, where τ is the average duration of one division, and Cnτ and Tnτ
are the time delayed cancer and T-cell concentrations, respectively. The coefﬁcient qT
is the probability that a T-cell survives the encounter with an activated leukemia cell.
Once a T-cell is stimulated, it exits the collection of interacting T-cells and re-enters
the system nτ time units later after n divisions.
The estimated universal and patient-dependent parameter values for this system
are given in Table 2 (and are taken from (Michor et al. 2005) and (Kim et al. 2008)).
The parameters n, sT , dT , and cn are patient-dependent parameters, and in (Kim et
al. 2008) the authors use experimental data for CML patients on imatinib treatment
published by Chen et al. (2008) to estimate values for these parameters for particular
patients. It is our goal here to demonstrate numerically that strategically timed treat
ment interruptions may lead to total eradication of cancerous cells, and we wish to
study here the activation of T-cells as a general feature, rather than to focus on partic
ular patient-dependent data sets. Thus, we will present detailed numerical results here
for simulations using the parameter values in Table 2, which are representative of the
parameter values for all patient data in (Chen et al. 2008). To study the impact of the
particular numerical values of the parameters on our results, we present an extensive
sensitivity analysis in Sect. 4, and we vary the parameters to include the ranges of the
parameter values for all patients analyzed in (Chen et al. 2008).
In Fig. 1, we illustrate the results of simulating the delay-differential equations
model presented in (Kim et al. 2008) without imatinib treatment, i.e., ay = 1.6 and
�
by = 10. We plot the total leukemia cell concentrations 3i =0 yi for 0 ≤ t ≤ 500 days.
We observe that without imatinib treatment, the cancer population grows rapidly.
Moreover, we note that without treatment, the immune response is fully suppressed
and the T-cell concentration remains at the initial steady state sT /dT .
Next, in Fig. 2, we illustrate the results of simulating the delay-differential equa
tions model of Kim et al. (2008) with continuous imatinib treatment, i.e., ay = 1.6/10
and by = 10/750. We plot the base-10 logarithm of the total leukemia cell concen
�
trations 3i =0 yi and the T-cell concentrations T (t) for 0 ≤ t ≤ 1200 days. In (Kim
et al. 2008), it has been demonstrated that this model that includes the anti-leukemia
T-cell response provides a closer ﬁt to the immunological data than the Michor model
(Michor et al. 2005) that does not include the immune response. In particular, we note
that the 2005 model of Michor et al. (2005) predicts that leukemia relapses after 15
to 24 months, despite continued imatinib treatment. However, this contradicts clini
cal observations in imatinib-treated patients, who generally remain in remission well
beyond 30–40 months, as described in Piazza et al. (2006). With the addition of the

Table 2 Estimates of parameters (Kim et al. 2008; Michor et al. 2005)
Parameter

Description

Estimate

λ

Fractional adjustment constant

0.75

d0

Stem cell death rate

0.003 λ/day

d1

Progenitor cell death rate

0.008 λ

d2

Differentiated cell death rate

0.05 λ

d3

Terminal cell death rate

λ

ry

Stem cell regeneration rate

0.008/day

ay

Stem cell growth rate

1.6 (without imatinib treatment)

by

Progenitor cell growth rate

10 (without imatinib treatment)

cy

Differentiated cell growth rate

100

rz

Imatinib resistant mutation

1.6/100 (with imatinib treatment)
10/750 (with imatinib treatment)

stem cell regeneration rate
az

mutation stem cell growth rate
bz

1.6

Imatinib resistant mutation
progenitor cell growth rate

cz

0.023/day

Imatinib resistant

10

Imatinib resistant mutation
differentiated cell growth rate

100

k

Kinetic (mixing) coefﬁcient

1 (k/µL)−1 /day

p0

Probability that T-cell engages cancer cell

0.8

qC

Probability that cancer cell dies from
encounter with T-cell

qT
τ

0.75

Probability that T-cell survives
encounter with cancer cell

0.5

Duration of one T-cell division

1 day

n

Average number of T-cell divisions

1.2

dT

Anti-leukemia T-cell death rate

0.001/day

sT

Anti-leukemia T-cell supply rate

1.2 × 10−6 (k/µL)/day

cn

Decay rate of immune responsivity

1 (k/µL)−1

y0 (0)

Initial leukemia stem cell concentration

1.8 × 10−5 k/µL

T-cell response in the model of Kim et al. (2008), persistence of anti-leukemia T-cells
even at low levels prevents leukemia from relapsing for up to 50 months.
The graphs in Fig. 2 illustrate several important points about the dynamics of CML
under imatinib treatment and the imatinib-induced immune response as described by
the DDE model of Kim et al. (2008). As soon as imatinib treatment begins, there
is a sharp decline in the leukemia cell concentrations. Although imatinib drives the
cancer population to low levels, it does not completely eliminate the leukemia stem
cells, and the result is a situation in which leukemia is never completely eliminated.
In particular, we note that the minimum total cancer concentration predicted by the

Fig. 1 Total leukemia
concentration without imatinib
treatment for 0 ≤ t ≤ 500 days

Fig. 2 The logarithm of the
leukemia concentration and the
T-cell concentration with
continuous imatinib treatment

model before cytogenetic relapse is 1.1 × 10−4 k/µL. Assuming that an average per
son has approximately 6 liters of blood, this concentration level corresponds to a total
leukemia cell population of half a million to a million cells. We also observe that the
model predicts that with continuous imatinib treatment, the patient will eventually
relapse. These observations demonstrate an important point, namely that the model
does not predict that CML is eliminated by imatinib treatment alone. However, the
model does predict that it takes signiﬁcantly more time for the disease to relapse
when compared with the Michor model that does not include the immune response.
In addition, we observe ﬂuctuations in the anti-leukemia T-cell concentrations that
correspond to changes in the leukemia cell concentrations. Initially, the T-cell con
centrations remain low, close to the steady-state level, as the immune response is fully
suppressed by leukemia. As the leukemia cell concentrations decrease, the patient’s
immune response is eventually stimulated and the T-cell concentrations increase ac

cordingly. When the leukemia cell populations become sufﬁciently low, the T-cells
are no longer stimulated and begin to contract. As a result, the immune response does
not expand sufﬁciently to eliminate the leukemia cells. It is clear from these obser
vations that there is a critical time period during which the anti-leukemia immune
response is activated. If the leukemia cell concentration is too high, the immune re
sponse is fully suppressed. On the other hand, if the leukemia cell concentration is
too low, the immune response will not be sufﬁciently stimulated. For reference, we
note that the T-cell population begins increasing at t = 90 days, and the maximum
T-cell concentration is 3.09 × 10−2 k/µL at t = 206 days.

3 Strategic Treatment Interruptions
Strategic treatment interruptions (STIs), also known as “structured treatment inter
ruptions” or “supervised treatment interruptions” are planned interruptions of drug
treatment designed to reduce and/or relieve the side effects of the drugs, to reduce
drug resistance, and/or to stimulate the immune response. In this section, we study
several treatment interruption plans for imatinib treatment of CML based on the math
ematical model for CML discussed in Sect. 2. In particular, we attempt to improve
the effectiveness of treatment by strategically interrupting imatinib treatment in order
to leverage the patient’s own anti-leukemia immune response.
Strategic treatment interruptions have been studied extensively for patients
with chronic HIV infection being treated with highly active antiretroviral therapy
(HAART) (Adams et al. 2004; Bajaria et al. 2004; Koup 2004; Maserati et al. 2007).
In this context, strategic treatment interruptions were motivated primarily by the de
velopment of drug resistance, evolution of viral strains, detrimental short- and longterm side effects, and patient complications (Bajaria et al. 2004). Numerous studies
have been conducted to explore the beneﬁts of strategic treatment interruptions for
HIV treatment, but the results vary widely and are highly dependent on treatment
schedules, starting times, and patient-speciﬁc factors.
In this work, however, we are primarily interested in the use of strategic treatment
interruptions as a technique for leveraging the patient’s own anti-leukemia immune
response to combat CML. In this ﬁrst study, we perform several simulations in which
we temporarily stop imatinib treatment once. We vary the length of the interruption
and the starting time of the interruption, and measure the time required for the patient
to achieve cytogenetic remission and the time required for total cancer elimination
(if total elimination occurs). We assume that when imatinib is stopped, the stem cell
and progenitor cell growth rates (ay and by , respectively) immediately return to their
values without imatinib treatment (1.6 and 10, respectively). Similarly, we assume
that when imatinib is restarted, ay returns to 1.6/100 and by returns to 10/750 imme
diately.
In Tables 3 and 4, we present the results of several 15-day and 30-day strate
gic treatment interruption simulations. In each of these studies, we simulate a single
treatment interruption in an attempt to leverage the ﬁrst immune response increase.
Imatinib treatment is temporarily stopped on a speciﬁed day for either 15 or 30 days.
In Fig. 3, we plot the base-10 logarithm of the total leukemia cell concentration and

Table 3 Results of several 15-day strategic treatment interruption (abbreviated as STI above) plans. For
each simulation, we report the ﬁrst day of the 15-day treatment interruption, the maximum leukemia con
centration that occurs after the interruption, the time required for the patient to achieve cytogenetic remis
sion, and the time required for total cancer elimination (i.e., concentration < 10−10 k/µL)
Treatment
plan: First
day of
15-day STI

Maximum leukemia
concentration
(k/µL) after
interruption

Time until
cytogenetic
remission
(days)

Time until
total cancer
elimination
(days)

No STI
90
120
150
180
210
240
270
300
330
360
390

n/a
20.6 at t = 106
17.25 at t = 136
14.58 at t = 166
11.71 at t = 196
8.96 at t = 226
6.75 at t = 256
5.14 at t = 286
4.01 at t = 316
3.21 at t = 346
2.64 at t = 376
2.23 at t = 406

251
312
313
316
329
346
365
386
408
433
459
487

n/a
n/a
n/a
879
665
616
606
611
627
655
693
739

Table 4 Results of several 30-day strategic treatment interruption (abbreviated as STI above) plans.
For each simulation, we report the ﬁrst day of the 30-day strategic treatment interruption, the maximum
leukemia concentration that occurs after the interruption, the time required for the patient to achieve cyto
genetic remission, and the time required for total cancer elimination (i.e., concentration < 10−10 k/µL)
Treatment
plan: First
day of
30-day STI

Maximum leukemia
concentration
(k/µL) after
interruption

Time until
cytogenetic
remission
(days)

Time until
total cancer
elimination
(days)

No STI
90
120
150
180
210
240
270
300
330
360
390

n/a
34.6 at t = 121
31.35 at t = 151
28.30 at t = 181
24.33 at t = 211
19.92 at t = 241
16.07 at t = 271
13.06 at t = 301
10.77 at t = 331
9.05 at t = 361
7.75 at t = 391
6.75 at t = 421

251
342
345
350
364
382
404
426
449
473
498
524

n/a
n/a
n/a
929
711
662
654
656
666
681
699
722

the T-cell concentrations for 0 ≤ t ≤ 1200 days with continuous imatinib treatment
(upper left), with a 15-day strategic treatment interruption from t = 300 days until
t = 315 days (upper right), and with a 30-day strategic treatment interruption from

Fig. 3 Logarithm of the leukemia concentrations and the T-cell concentrations for 0 ≤ t ≤ 1200 days
with continuous imatinib treatment (upper left), with a 15-day treatment interruption (STI) from t = 300
to t = 315 days (upper right), and with a 30-day treatment interruption from t = 180 to t = 210 (lower).
The treatment interruption is indicated with vertical lines

t = 180 days until t = 210 days (lower). In each graph, the timing of the treatment
interruption is marked with vertical lines. These graphs demonstrate the general dy
namics of the leukemia and T-cell concentrations for all the simulations described
in Tables 3 and 4, so we include only these illustrative cases here. For ease of com
parison amongst the scenarios, the axis scales (minimum and maximum values) are
the same for each of the three treatment strategies presented in Fig. 3. With the start
of imatinib treatment at time t = 0, the leukemia cell concentration begins decreas
ing rapidly, and at approximately 90 days, the leukemia cell concentration is small
enough that the immune response is no longer signiﬁcant and the T-cell concentra
tion begins increasing. As a result of the strategic treatment interruption, there is a
small, fast rise in the concentration of leukemia cells while the imatinib treatment
is stopped. However, this increase does not reach the initial level of leukemia cells
present in the patient. Eventually, after imatinib treatment is restarted, the leukemia
cell concentration falls below the level of cytogenetic remission. For the second case
(treatment interruption for 300 ≤ t ≤ 315 days) illustrated in Fig. 3, the leukemia
concentration ﬁrst falls below the level of cytogenetic remission 408 days after the
start of treatment, and after 627 days, cancer has been completely eliminated.
In each table, we present the ﬁrst day of the treatment interruption, the maxi
mum leukemia cell concentration that occurs after the treatment interruption occurs,

Fig. 4 Summary of the results of several 15-day and 30-day strategic treatment interruptions. Upper left:
The maximum leukemia concentration (k/µL) that occurs after the interruption vs. starting day of the
treatment interruption. Upper right: Time (in days) until cytogenetic remission vs. starting day of the
treatment interruption. Lower: Time (in days) until complete leukemia elimination vs. starting day of the
treatment interruption

the time required for the patient to achieve cytogenetic remission, and the time re
quired for total cancer elimination (i.e., total concentration <10−10 k/µL). In almost
all cases, the strategic treatment interruption strategies that we consider result in total
cancer elimination within the ﬁrst 3 years of treatment. For reference, we note that
the minimum total cancer concentration predicted by the mathematical model with a
15-day treatment interruption beginning at t = 300 is 1.52 × 10−26 k/µL, which cor
responds to a total cancer cell count of 9.12 × 10−17 cells (assuming 6 L of blood).
This minimum concentration is signiﬁcantly lower than (several orders of magnitude)
the cancer elimination criterion of 10−10 k/µL.
We summarize the results presented in Tables 3 and 4 with a series of graphs. In
Fig. 4, we plot the maximum leukemia concentration (k/µL) that occurs after the
interruption vs. starting day of the treatment interruption (upper left); the time (in
days) until cytogenetic remission vs. starting day of the treatment interruption (upper
right); and the time (in days) until complete leukemia elimination vs. starting day of
the treatment interruption (lower).

In Sect. 4, we perform several hundred simulations in which we vary the para
meters in Tables 2 over a wide range that includes the biologically relevant values
determined by the data presented in (Chen et al. 2008).
The results presented in Tables 3 and 4 demonstrate that there is a tradeoff between
the starting time of the treatment interruption, the maximum cancer concentration ob
served after the interruption, and the time required for the patient to achieve cytoge
netic remission and total cancer elimination. As the starting time of the interruption
increases, the maximum cancer concentration observed due to the spike after imatinib
is stopped decreases, and the time required until cytogenetic remission and total can
cer elimination increases. Thus, before clinical implementation of strategic treatment
interruptions for CML patients, these issues should be studied in more detail, and the
individual treatment goals of each patient should be taken into consideration when
devising a treatment plan.

4 Sensitivity Analysis
In this section, we conduct a sensitivity analysis of the model parameters with respect
to the effectiveness of the strategic treatment interruption strategies. We apply the
Latin Hypercube sampling (LHS) method described in (McKay et al. 1979). The LHS
technique provides a method for simultaneously sampling a wide range of parameters
and statistically determining the correlation between the values of the parameters and
various outcomes. We simulate the delay-differential equation model with various
strategic treatment interruptions several thousand times with randomly sampled sets
of parameters; using LHS, the values of the parameters are chosen in such a way that
each parameter is well distributed over its range of possible values. In particular, the
parameters are sampled uniformly over the ranges given in Table 5. We vary every
parameter and initial condition used in the model.
We provide in Table 5 the Pearson product-moment correlation (PPMC) and
Spearman rank-order correlation (SROC) coefﬁcients between each parameter and
the minimum cancer concentration attained during the course of treatment before the
model predicts a relapse above the level of cytogenetic remission. To obtain the cor
relation coefﬁcients in Table 5, we performed 1000 LHS simulations with a strategic
treatment interruption from t = 300 to t = 315 days after the start of treatment, but
we note that the correlation coefﬁcients obtained with all other strategic treatment
interruption strategies considered in Sect. 3 are comparable. We also note that the
relationship between the parameter values and the minimum cancer concentration is
monotonic.
As indicated in Table 5, the most sensitive parameters are n (the average number
of T-cell divisions per stimulation), qT (the probability that a T-cell survives an en
counter with a leukemia cell), and cn (the rate of exponential decay in the probability
of a productive T-cell interaction with a cancer cell, or the level of immune downregulation). Since we are speciﬁcally timing the interruption to leverage the patient’s
own immune response, it makes sense that the parameters that are most sensitive to
the effectiveness of treatment are those that are directly related to T-cell activity. We
note that as a potential clinical application for treatment of CML, these parameters

Table 5 Sensitivity analysis of the parameters used in the DDE model for a 15-day strategic treatment
interruption from t = 300 to t = 315. For each parameter, we report the estimate of the parameter, the range
used for Latin Hypercube sampling, and the Pearson product-moment correlation (PPMC) and Spearman
rank-order correlation (SROC) coefﬁcients between the parameter and the minimum cancer concentration.
To obtain the correlation coefﬁcients, we performed 1000 simulations in which every parameter was varied
over the given range
Parameter

Estimate

Range

PPMC

SROC

λ

0.75

0.5 to 1

−0.1438

−0.0866

d0

0.003 λ/day

±25%

−0.0217

0.0158

d1

0.008 λ

±25%

−0.0135

0.0625

d2

0.05 λ

±25%

−0.1238

0.0566

d3

λ

±25%

0.0364

0.0718

ry

0.008/day

±25%

0.0342

0.0195

ay

1.6 without imatinib

±25%

0.0224

−0.0235

±25%

0.0218

0.0077

1.6/100 with imatinib
by

10 without imatinib
10/750 with imatinib

cy

100

±25%

0.0668

−0.0708

rz

0.023 /day

±25%

−0.0319

−0.0323

az

1.6

Same as ay

0.0224

−0.0235

bz

10

Same as by

0.0218

0.0077

cz

100

Same as cy

0.0668

−0.0708

u

0/division

4 × 10−8 − 8 × 10−8

−0.0854

−0.0889

k

1 (k/µL)−1 /day

±25%

−0.0871

−0.1246

p0

0.8

±25%

−0.0981

−0.1298

qC

0.75

±25%

−0.0307

−0.0526

qT

0.5

±25%

−0.1174

−0.2229

τ

1 day

12–24 hours

0.0732

0.1217

n

1.17 to 2.2

1 to 3

−0.2534

−0.4543

dT

1 − 7 × 10−3 d/ay

1 × 10−3 to 1 × 10−2

0.1444

0.0372

1 × 10−5 to 1 × 10−6 k/µL/day

1 × 10−5 to 1 × 10−6

−0.0499

−0.0852

cn

0.8 to 7/day

0 to 10

0.1637

0.3921

C(0)

23.1–116.8 k/µL

20 to 200

0.0947

0.0414

sT

should be measured before and during treatment so that the strategic treatment in
terruption plan can be constructed to optimize the anti-leukemia immune response.
In addition, in Table 6 we present the results of several thousand strategic treatment
interruption simulations using the parameter ranges described in Table 5. In partic
ular, for each strategic treatment interruption, we perform 500 simulations in which
every parameter is randomly varied over the ranges given in Table 5. In Table 6, we
report the fraction of these simulations that result in a successful treatment. Here, a
successful treatment is a simulation in which the total cancer population falls below
the total elimination criterion.

Table 6 Results of LHS sensitivity analysis of the parameters in Table 5. For each strategic treatment
interruption (abbreviated as STI above) plan, 500 simulations are performed in which every parameter is
randomly varied over the ranges given in Table 5. We report the fraction of LHS samples that result in a
successful treatment. A success is deﬁned as a simulation in which the total cancer population falls below
10−10 k/µL
Treatment

Fraction of

Treatment plan:

plan:

successful

plan:

Fraction of
successful

STI days

treatments

STI days

treatments

90 ≤ t ≤ 105

0.488

120 ≤ t ≤ 135

0.544

150 ≤ t ≤ 165

0.568

180 ≤ t ≤ 195

0.450

210 ≤ t ≤ 225

0.544

240 ≤ t ≤ 255

0.546

270 ≤ t ≤ 285

0.468

300 ≤ t ≤ 315

0.650

330 ≤ t ≤ 345

0.512

360 ≤ t ≤ 375

0.486

390 ≤ t ≤ 405

0.474

90 ≤ t ≤ 120

0.434

120 ≤ t ≤ 150

0.458

150 ≤ t ≤ 180

0.480

180 ≤ t ≤ 210

0.516

210 ≤ t ≤ 240

0.542

240 ≤ t ≤ 270

0.566

270 ≤ t ≤ 300

0.588

300 ≤ t ≤ 330

0.624

330 ≤ t ≤ 360

0.578

360 ≤ t ≤ 390

0.550

390 ≤ t ≤ 420

0.542

90 ≤ t ≤ 135

0.450

150 ≤ t ≤ 195

0.524

210 ≤ t ≤ 255

0.578

270 ≤ t ≤ 315

0.624

330 ≤ t ≤ 375

0.528

390 ≤ t ≤ 435

0.536

450 ≤ t ≤ 495

0.530

510 ≤ t ≤ 555

0.544

570 ≤ t ≤ 615

0.528

630 ≤ t ≤ 675

0.526

690 ≤ t ≤ 735

0.518

750 ≤ t ≤ 795

0.494

5 Discussion and Concluding Remarks
In this paper, we have presented the results of numerous strategic treatment inter
ruption simulations for CML patients being treated with imatinib. This study used
the mathematical model presented in (Kim et al. 2008), which models the dynamics
between CML, imatinib, and the patient’s own immune response, to simulate strate
gic treatment interruption programs designed to leverage the anti-leukemia immune
response. Mathematical modeling is an important tool for investigating the dynam
ics of this complex system, and it provides the ability to simulate and investigate
treatment interruption therapy techniques as a possible treatment for CML patients.
We have demonstrated numerically that strategically-timed imatinib treatment inter
ruptions could lead to a potential cure for CML, and that the effectiveness of the
treatment depends on the starting time of the treatment interruption and the length of
time that imatinib treatment is stopped.
In this ﬁrst study, we have used numerical results (such as the time required for
total cancer elimination) to make general observations about the effectiveness of dif
ferent start times and durations for various treatment interruption programs. In the
future, we plan to study this optimization problem in more detail; we also plan to
consider treatment interruption programs in which treatment is stopped more than

once. In (Kim et al. 2008), the authors presented a vaccination strategy as a possible
immunotherapy treatment for CML, and in a future work, we plan to study combina
tions of strategic treatment interruptions and vaccinations as a possible treatment for
CML.
There are two major drawbacks to the delay differential equations model of Kim et
al. (2008) that we have used to perform numerical simulations of strategic treatment
interruption plans. First, the model does not consider competition among hemapoetic
stem cells. In (Dingli and Michor 2006), Dingli and Michor presented a mathemati
cal model for cancer stem cell development that assumes that normal stem cells and
tumor stem cells compete for a common resource. Similarly, in (Roeder and Glauche
2008), Roeder and Glauche presented a mathematical model which assumes a sto
chastic competition between normal stem cells and tumor stem cells. Although there
is not sufﬁcient quantitative data on the growth dynamics of stem cells in patients be
fore diagnosis to validate one of these models over another, the models that consider
competition among hemapoetic stem cells are consistent with current clinical data
(Roeder and Glauche 2008), and in a future work, we plan to numerically simulate
strategic treatment interruptions using the mathematical models presented in (Dingli
and Michor 2006) and (Roeder and Glauche 2008). Generally, we hypothesize that
the inclusion of such a competition process would actually improve the results of
strategic treatment interruptions. During imatinib treatment of CML, competition be
tween normal and tumor cells has the effect of increasing the time that CML remains
in remission. During a treatment interruption, on the other hand, CML is expected to
relapse, and the leukemia cell population will quickly overpower the normal cell pop
ulation during a relapse. Thus, the relatively small population of normal cells present
during a relapse will provide little competition.
Second, we have not considered here the possibility of imatinib-resistant muta
tions. In (Komarova and Wodarz 2005), the authors presented a mathematical frame
work for the emergence of cancers treated with targeted drugs, and for the speciﬁc
case of CML, the authors estimate that imatinib-resistant stem cells are generated
maximally at a rate of 10−9 –10−8 mutations per division. In future work, we plan to
study in detail the effects of imatinib-resistant mutations on strategic treatment inter
ruptions. In particular, we plan to add a set of imatinib-resistant leukemia cells to the
delay differential equations model of Kim et al. (2008), and to derive new parameter
values with resistant cells using the patient data presented in (Chen et al. 2008) and
(Kim et al. 2008). We note that a treatment interruption may potentially impose an
increased risk of mutations, as drug resistant mutations may be more likely to emerge
when the patient stops taking imatinib and only low levels remain. For example, in
(Koup 2004), the author observed that although researchers were initially enthusiastic
about the possibility of successfully treating HIV with strategic treatment interrup
tions (primarily to give patients a respite from side effects), several clinical trials
demonstrated that patients developed an increased amount of drug resistance while
receiving strategic treatment interruptions. This observation has since been repeated
in several other studies on the use of treatment interruptions during antiretroviral
therapy for HIV patients. Thus, the potential effects of treatment interruptions on the
resistance mutation rate for CML patients should be thoroughly investigated.
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Appendix A: Exact Solution of the Michor Model
The system of ODEs that describes the mathematical model of Michor et al. (2005) is
given below. We include here the second set of differential equations which describe
the dynamics of the imatinib-resistant leukemia cells. These populations are denoted
z0 , z1 , z2 , z3 (imatinib-resistant stem cells, progenitor cells, differentiated cells, and
terminally differentiated cells, respectively).
dy0
dt
dy1
dt
dy2
dt
dy3
dt

�
�
= ry (1 − u) − d0 y0 ,

dz0
= (rz − d0 )z0 + ry uy0 ,
dt

dz1
= az z0 − d1 z1 ,
dt
dz2
= bz z1 − d2 z2 ,
dt
dz3
= cz z2 − d3 z3 .
dt

= a y y 0 − d1 y 1 ,
= b y y 1 − d2 y 2 ,
= c y y 2 − d3 y 3 ,

(A.1)

To ﬁnd the exact solution of this system of ODE’s given, we ﬁrst write the system
in matrix form x� = Ax, where
�
x = y0

y1

y2

y3

z0

z1

z2

z3

�T

and A is the coefﬁcient matrix of the system. The eigenvalues of the coefﬁcient matrix
A are given by
λ0 = ry (1 − u) − d0 ,
λ1 = −d1 ,

λ5 = −d1 ,

λ2 = −d2 ,

λ6 = −d2 ,

λ3 = −d3 ,

λ7 = −d3 ,

λ4 = rz − d0 ,

and we obtain the following explicit solution of the Michor model for CML:
y0 (t) = α0 e(ry (1−u)−d0 )t ,
y1 (t) = α1 e−d1 t −

ay α0
e(ry (1−u)−d0 )t ,
ry (u − 1) + d0 − d1

(A.2)

y2 (t) = α2 e−d2 t +
−

by (−α1 ry + α1 ury + α1 d0 − α1 d1 ) −d1 t
e
(−ry (1 − u) + d0 − d1 )(d2 − d1 )

α0 by ay
e(ry (1−u)−d0 )t ,
(−ry (1 − u) + d0 − d1 )(ry (1 − u) − d0 + d2 )

y3 (t) = α3 e−d3 t −

α0 ay by cy
(ry (1 − u) + d3 − d0 )(ry (u − 1) + d0 − d2 )(ry (1 − u) + d1 − d0 )

× e(ry (1−u)−d0 )t
α1 by cy
α2 cy −d2 t
+
e
−
e−d1 t ,
d 3 − d2
(d3 − d1 )(d1 − d2 )
α0 ry u
z0 (t) = β0 e(rz −d0 )t −
e(ry (1−u)−d0 )t ,
ry (u − 1) + rz
β0 az (ry (u − 1) + rz )
e(rz −d0 )t
(ry (u − 1) + rz )(rz − d0 + d1 )
α0 ury az
−
e(ry (1−u)−d0 )t ,
(ry (u − 1) + rz )(ry (1 − u) − d0 + d1 )

z1 (t) = β1 e−d1 t +

z2 (t) = β2 e−d2 t +

α0 ry uaz bz
(ry (1 − u) − d0 + d2 )(ry (u − 1) + rz )(ry (u − 1) + d0 − d1 )

× e(ry (1−u)−d0 )t
β1 bz −d1 t
β0 az bz
+
e(rz −d0 )t +
e
,
(rz − d0 + d2 )(rz − d0 + d1 )
d 2 − d1
z3 (t) = β3 e−d3 t +

β1 bz cz
β2 cz −d2 t
e−d1 t +
e
(d2 − d1 )(d3 − d1 )
d 3 − d2

+

α0 ry uaz bz cz · e(ry (1−u)−d0 )t
(ry (u − 1) + d0 − d1 )(ry (1 − u) − d0 + d2 )(ry (1 − u) − d0 + d3 )(ry (u − 1) + rz )

+

β0 az bz cz
e(rz −d0 )t ,
(rz − d0 + d1 )(rz − d0 + d2 )(rz − d0 + d3 )

where the αi and βi are arbitrary constants of integration that are determined by the
initial conditions of the leukemia cell populations. Since the solutions yi and zi are all
linear combinations of exponential functions, it is clear that the long-term behavior of
the system depends only on the relative sizes of the eigenvalues λi , i = 0..7. For the
particular values of the parameters given in Table 2, the only positive eigenvalues are
ry (1 − u) − d0 and rz − d0 , so the leukemia stem cell populations y0 and z0 dominate
the dynamic of this system.
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